Scholars Central

CommentaryPublished 28 Jan 2022

Drug design with Artificial Intelligence

Authors: Lily Williams

Health Economics & Outcome Research: Open Access

Volume 8 · Issue 1 · Pages 1–5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Drug research relies heavily on Artificial Intelligence (AI). Artificial neural networks, such as deep neural networks and recurrent networks, are very important in this field. Numerous applications in property or activity predictions, such as physicochemical and ADMET characteristics, have lately emerged, demonstrating the technology's strength in Quantitative Structure-Property Relationships (QSPR) and Quantitative Structure-Activity Relationships (QSAR) (QSAR). De novo design uses artificial intelligence to guide the creation of new biologically active molecules that have the desired features. Artificial intelligence's strength in this subject is demonstrated by several cases. Combining synthesis planning and ease of synthesis is possible, and computer-aided drug discovery is predicted to become more common in the near future.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Health Economics & Outcome Research: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalHealth Economics & Outcome Research: Open Access
  • SubjectBusiness & Management
  • SubjectNursing & Healthcare
  • BylineArticles whose byline prints “Lily Williams”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels